ERBB2 and metastatic neoplasm: A study carried out by Biswas et al. in 2017 combined whole genome sequencing (WGS) with MS-proteomics to analyze the primary and metastatic tumor profile of a patient with metastatic lung adenocarcinoma receiving ERBB2-targeted therapy [27].